MaxCyte buys into CAR-T with Johns Hopkins partnership

Maryland biotech MaxCyte is delving into the world of CAR-T treatments for cancer, teaming up with Johns Hopkins University on a preclinical program. The two plan to develop treatments that rewire patients' own immune cells to better detect and attack cancer, outfitting T cells with chimeric antigen receptors, or CARs. CAR-T therapies have thus far demonstrated excellent early results in blood cancers, and, building on that principle, MaxCyte and JHU are targeting solid tumors with their research. Release